GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (NAS:GWPH) » Definitions » EPS without NRI

GW Pharmaceuticals (GW Pharmaceuticals) EPS without NRI : $-2.16 (TTM As of Mar. 2021)


View and export this data going back to 2013. Start your Free Trial

What is GW Pharmaceuticals EPS without NRI?

GW Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2021 was $-0.60. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2021 was $-2.16.

During the past 12 months, GW Pharmaceuticals's average earnings per share (NRI) Growth Rate was -325.00% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 35.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 27.10% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for GW Pharmaceuticals's EPS without NRI or its related term are showing as below:

GWPH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -92   Med: -9.05   Max: 61.1
Current: 35.5

During the past 13 years, GW Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 61.10% per year. The lowest was -92.00% per year. And the median was -9.05% per year.

GWPH's 3-Year EPS without NRI Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 11.65 vs GWPH: 35.50

GW Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2021 was $-0.60. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $-2.16.

GW Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2021 was $-0.60. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2021 was $-2.16.


GW Pharmaceuticals EPS without NRI Historical Data

The historical data trend for GW Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GW Pharmaceuticals EPS without NRI Chart

GW Pharmaceuticals Annual Data
Trend Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.08 -6.72 -10.56 -0.24 -1.80

GW Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.24 -0.36 -0.96 -0.60

Competitive Comparison of GW Pharmaceuticals's EPS without NRI

For the Drug Manufacturers - General subindustry, GW Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GW Pharmaceuticals's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GW Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where GW Pharmaceuticals's PE Ratio without NRI falls into.



GW Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GW Pharmaceuticals  (NAS:GWPH) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


GW Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ
GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.
Executives
Douglas B. Snyder officer: Chief Legal Officer SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB249BZ
Volker Knappertz officer: Chief Medical Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Cabot Brown director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Adam D. George officer: Secretary SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Guy Geoffrey W Dr director, officer: Executive Chairman ETHICAL HOLDINGS PLC CORPUS CHRISTI HOUSE 9 WEST STREET GODMANCHESTER CAMBRIDGESHIRE PE18 A1
Christopher J. Tovey officer: Chief Operating Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Justin D. Gover director, officer: Chief Executive Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
James Noble director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421
Darren S Cline officer: U.S. Chief Commercial Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
William A. Waldegrave director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Julian S Gangolli officer: President, North America 4955 BASELINE AVENUE, SANTA YNEZ CA 93460

GW Pharmaceuticals (GW Pharmaceuticals) Headlines

From GuruFocus

Gw Pharmaceuticals Plc (GWPH) COO Christopher J. Tovey Sold $1.4 million of Shares

By GuruFocus Research GuruFocus Editor 12-03-2020